網頁Patients and methods: This study included 71 patients with metastatic castration-resistant prostate cancer treated by docetaxel chemotherapy with co-introduction of a steroid. PSA flare was defined as a transient PSA increase followed by a PSA decrease. Results: PSA flare was recognized in 7.0-23.9% of patients according to the definition used. 網頁Zurück zum Zitat Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512 CrossRefPubMed Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Co-introduction of a steroid with docetaxel chemotherapy for …
網頁Background: The administration of docetaxel requires the use of dexamethasone for the prevention of hypersensitivity reactions (HSRs) and fluid retention reactions (FRRs). The … 網頁In an attempt to balance the benefits and harms of steroid prophylaxis without affecting the safety of docetaxel, this study tried to reduce the duration and dose of dexamethasone. Methods: In this study, a total of 336 patients underwent docetaxel-containing protocols (TP or TPF regimens) to treat head and neck neoplasms. adenomatoid odontogenic tumor pathology
Masitinib Plus Docetaxel Improves PFS in Metastatic Castration-Resistant Prostate Cancer …
網頁2013年5月6日 · Adjuvant-based docetaxel may lead to well-known acute and chronic adverse events including neutropenic fever or infection, stomatitis, hypersensitive reaction, rash, fluid retention, peripheral neuropathy, and fatigue. The safety profile of docetaxel is schedule and dose dependent. 網頁2024年6月9日 · For treating men with de novo metastatic castration-sensitive prostate cancer (mCSPC), adding abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved radiographic progression-free survival (rPFS), according to results presented at the 2024 American Society of Clinical Oncology … 網頁Similarly, in the SWOG 9916 trial, 11 which compared docetaxel plus estramustine with mitoxantrone plus prednisone, mOS was longer in the group receiving docetaxel and estramustine (17.5 months vs 15.6 months), with a HR of 0.8 (95% CI: 0.67–0.97; P=0. journal of lipid research インパクトファクター